Hong Kong Stock Movement
INSILICO rose 10.02%. Based on recent key news:
<ol>
<li>
On January 5, INSILICO reached a research and development cooperation worth USD 888 million with Schwabe, driving the stock price up. This cooperation will utilize the Pharma.AI platform to develop anti-tumor drugs, and INSILICO is eligible to receive a USD 32 million upfront payment and milestone payments. Source: Zhitong Finance
</li>
<li>
On January 5, INSILICO's stock price has accumulated a rise of 55.43% since its listing on the Hong Kong Stock Exchange, with market recognition of its AI pharmaceutical model driving the stock price up. Source: Dongfang Caifu
</li>
<li>
On January 5, INSILICO's IPO performed strongly, with oversubscription breaking records, attracting top global investors and enhancing market confidence. Source: Zhitong Finance. The AI pharmaceutical market has significant potential, with noticeable capital inflow.
</li>
</ol>
Stocks with High Trading Volume in the Industry
BRAINAURORA-B rose 4.99%. Based on recent key news:
<ol>
<li>
On January 6, BRAINAURORA-B signed an important business cooperation agreement with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to promote the research and commercialization of digital therapy products for mental health. This move consolidates the company's first-mover advantage in this field, accelerates product development and commercialization processes, and enhances the company's core position in the &#34;industry, academia, research, and medical&#34; collaborative innovation system.
</li>
<li>
On January 5, a subsidiary of BRAINAURORA-B signed a cooperation agreement with Beijing Jianguo Medical for a cognitive digital therapy project, where both parties will collaborate on constructing and promoting applications in cognitive function assessment training for mental health scenarios, promoting the standardization, scaling, and accessibility of digital therapies for cognitive disorders.
</li>
<li>
On January 7, BRAINAURORA-B shareholders deposited stocks with Guotai Junan (Hong Kong), with a market value of HKD 1.959 billion, accounting for 20.77%. This move shows investors' confidence in the company's future development. The field of digital therapy for mental health is developing rapidly.
</li>
</ol>
YIDU TECH fell 0.88%. Based on recent news:
<ol>
<li>
On January 7, AI is reshaping medical processes, with domestic AI medical coverage spanning all chains from diagnosis to pharmaceuticals. YIDU TECH has integrated the DeepSeek AI model into its self-developed YiduCore platform, promoting technological advancement, but the market reaction was below expectations, leading to a decline in stock price.
</li>
<li>
On January 8, analysts pointed out that although YIDU TECH has made progress in the AI medical field, it failed to timely reflect the latest price-sensitive company announcements or qualitative materials, leading to insufficient investor confidence, which affected stock performance.
</li>
<li>
The AI medical market is expected to have a compound annual growth rate of 43.1% over the next decade.
</li>
</ol>
MEDLIVE fell 3.24%. Based on recent key news:
<ol>
<li>On January 5, MEDLIVE announced the issuance of 930,000 ordinary shares. According to the pre-IPO stock purchase rights plan, ordinary shares were issued to two company directors and one employee, leading to market concerns about equity dilution, causing the stock price to drop by 3.24%. Source: Zhitong Finance. The Hong Kong stock market has been volatile recently, and investors should exercise caution
Stocks Ranked Among the Top by Market Capitalization in the Industry</li>
</ol>
Xunfei Medical Technology fell by 1.15%. Based on recent key news:
<ol>
<li>
On January 5th, Xunfei Medical Technology leveraged its parent company iFLYTEK's self-developed &#34;Spark&#34; large model to enhance its access advantages in the government and large public hospital markets. This model is trained based on domestic computing power, ensuring data security and autonomy, which drives stock price fluctuations.
</li>
<li>
On January 5th, AI + healthcare became a policy growth direction, and Xunfei Medical Technology, as an industry leader, benefits from policy support. The National Health Commission and other departments have clearly stated that AI will enhance the diagnostic and treatment levels at the grassroots level, optimize the allocation of medical resources, and drive stock price fluctuations.
</li>
<li>
On January 5th, profit forecasts indicate significant revenue growth from 2025 to 2027, with positive market expectations. The projected revenues are 930 million yuan, 1.21 billion yuan, and 1.58 billion yuan, corresponding to PS ratios of 8.5 times, 6.5 times, and 5 times, driving stock price fluctuations. The policy support for the AI healthcare industry is increasing
</li>
</ol>

03696

06681

02158

02192

02506

INSILICO rose 10.02%; BRAINAURORA-B rose 4.99%, with a transaction volume of HKD 436 million; YIDU TECH fell 0.88%, with a transaction volume of HKD 29.76 million; MEDLIVE fell 3.24%, with a transaction volume of HKD 27.04 million; XUNFEIHEALTH fell 1.15%, with a market value of HKD 9.743 billion

HK Stock Movers Tracker

INSILICO

BRAINAURORA-B

YIDU TECH

MEDLIVE

XUNFEIHEALTH

Hong Kong Stock Movement: INSILICO rises 10.02%, $888 million cooperation and IPO boom boost stock price